S. 476 · 118th Congress · Senate

Maintaining Investments in New Innovation Act

Active· Read twice and referred to the Committee on Finance.
Introduced
Feb 16, 23
Passed Senate
Pending
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Action Timeline

2
  1. FEB 16, 2023IntroReferral

    Introduced in Senate

  2. FEB 16, 2023IntroReferral

    Read twice and referred to the Committee on Finance.

Committees

1

Finance Committee

ssfi00

Referred: Feb 16, 2023

Active